Experimental virus and CAR t combo takes on Hard-to-Treat GI cancers

NCT ID NCT07544589

Recruiting now Disease control Sponsor: Dispatch Biotherapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study aims to find a safe dose and see if it shrinks tumors, but it is still very experimental and involves significant risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DISP-10 (a combination of an adenovirus called DV-10 and BCMA-directed CAR T cells called ide-cel)
What this could lead to: If it works, this could point toward a new treatment option for advanced gastrointestinal cancers that are hard to treat.
What could go wrong: This is a very early Phase 1 trial with only 66 participants, so it may not work or could have serious side effects. The combination therapy is complex and carries risks like severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus adenoviridae infectious disease colorectal adenocarcinoma colorectal cancer colorectal neoplasm digestive system neoplasm esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER ESOPHAGEAL ADENOCARCINOMA GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL ADENOCARCINOMA

Contacts and locations

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
University of Cincinnati Cancer Center
RECRUITING

Cincinnati, Ohio, 45267, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.